Drug Discovery

Summit Therapeutics awarded BARDA contract to develop Ridinilazole for CDI

Summit Therapeutics announces that the Biomedical Advanced Research and Development Authority (BARDA), an agency of the US government's Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, has awarded Summit a contract worth up to $62m.

Janssen scraps hepatitis C development program

Janssen Sciences Ireland UC has scrapped its ongoing hepatitis C development program citing the growing number of therapies available for treating the disease effectively.

Boehringer Ingelheim, Gubra to develop next generation obesity treatments

Boehringer Ingelheim and Gubra announce a collaboration and license agreement for the development of novel peptide compounds to treat obesity.

European Investment Bank grants €75m funding for Evotec

Evotec and the European Investment Bank (EIB) announced that the EIB has granted Evotec an unsecured loan facility of up to €75m to support Evotec's Innovate strategy.

GSK exercises option on phase I/II NY-ESO T-cell therapy

GSK announced that it has exercised the option to obtain an exclusive global license from Adaptimmune for an investigational SPEAR T-cell receptor therapy targeting NY-ESO-1 (GSK3377794).

PATH boosts leadership in developing and introducing urgently needed vaccines

PATH has received a $120m grant from the Bill & Melinda Gates Foundation to further strengthen its PATH Center for Vaccine Innovation and Access (CVIA), which works across every stage of vaccine research, development, and introduction for diseases in low-resource settings.

Avadel secures exclusive rights to nocturia candidate Noctiva in US and Canada

Avadel Pharmaceuticals has entered into a license agreement with Serenity Pharmaceuticals, which grants Avadel the sole right to commercialize and further develop Noctiva in the US and Canada.

Tick saliva may reduce HIV-linked heart disease risk, says scientists

Scientists may have found a clue to why people living with HIV have double the likelihood of developing heart disease.

Genmab, Seattle Genetics to co-develop tisotumab vedotin for solid tumors

Genmab and Seattle Genetics announced that Seattle Genetics has exercised its option to co-develop tisotumab vedotin.